Low-molecular-weight heparin inhibition in classical complement activaton pathway during pregnancy

Thrombosis Research

Volumn 125, Issue 5, 2010, Pages

  Oberkersch, Roxana ^a   Attorresi, Alejandra I ^a   Calabrese, Graciela C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

C1q subunit; Complement; Glycosaminoglycans; LMWH; pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10; COMPLEMENT COMPONENT C1Q; ENOXAPARIN; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; FEMALE; HEMOLYSIS; HUMAN; IMMUNODIFFUSION; IN VITRO STUDY; PREGNANCY; PRIORITY JOURNAL; PROTEIN INTERACTION; THROMBOEMBOLISM;

ADOLESCENT; ADULT; COMPLEMENT PATHWAY, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; YOUNG ADULT;

EID: 77951665492     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.030     Document Type: Article

References (42)

1. Marchetti M., Vignoli A., Russo L., Baducci D., Pagnoncelli M., Barbui T., et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121 5 (2008) 637-645
2. Takasaki H., Ebihara S., Okazaki T., Asada M., and Yamayaya M. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumor angiogenesis and heparanase activity. Br J Pharmacol 146 3 (2005) 333-343
3. Yang L., Butcher M., Simon R.R., Osip S.L., and Shaughnessy S.G. The effect of heparin on osteoblast differentiation and activity in primary cultures of bovine aortic smooth muscle cells. Atherosclerosis 179 1 (2005) 79-86
4. Deepa P.R., and Varalakshimi P. Favourable modulation of the inflammatory changes in hypercholesterolemic atherogenesis by low molecular weight heparin. Int J Cardiol 106 3 (2006) 338-347
5. Young E. The antiinflammatory effects of heparin related compounds. Thromb Res 122 6 (2008) 743-752
6. Kishore U., and Reid K.B. C1q; structure, function and receptors. Immunopharm 49 (2000) 159-170
7. Johnson S., Michalak M., Opas M., and Eggleton P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol 11 (2001) 122-129
8. Ogden C.A., deCathelineau A., Hoffmann P.R., Bratton D., Ghebrehiwet B., Fadok V.A., et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiate macropinocytosis. J Exp Med 194 6 (2001) 781-795
9. Edelson B.T., Stricker T.P., Li Z., Dickeson S.K., Shepherd V.L., Santoro S.A., et al. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood 107 (2006) 143-150
10. van den Berg R.H., Fabber-Krol M.C., Sim R.B., and Daha M.R. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6 and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 161 (1998) 6924-6930
11. Fraser D.A., Bohlson S.S., Jasinskiene N., Rawal N., Palmarini G., Ruiz S., et al. C1q and MBL components of the innate immune system influence monocyte cytokine expression. J Leukoc Biol 80 (2006) 107-116
12. Almeda S., Rosenberg R.D., and Bing D.H. The binding properties of human complement component C1q; interaction with mucopolysaccharides. J Biol Chem 258 (1983) 785-791
13. Calabrese G.C., Leocata Nieto F., Recondo E.F., and Fernandez de Recondo M.E. An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system. Cell Mol Biol 47 17 (2001) 127-131
14. Calabrese G.C., Recondo E.F., and de Recondo M.E.F. Antithrombin and first complement protein recognizes the same active heparin fraction. Thromb Res 105 (2002) 537-541
15. Girardi G., Bulla R., Salmon J.E., and Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 43 (2006) 68-77
16. Girardi G. Guilty as charged: all available evidence implicates complement ́s role in fetal demise. Am J Reprod Immunol 59 3 (2008) 183-192
17. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003) 1644-1654
18. Girardi G., Redecha P., and Salomón J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 (2004) 1222-1226
19. Kher A., Bauersachs R., and Nielsen J.D. The management of thrombosis pregnancy: role of low-molecular-weight heparin. Thromb Haemost 97 (2007) 505-513
20. Ní Ainle F., Wong A., Appleby N., Byrne B., Regan C., Hassan T., et al. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 19 7 (2008) 689-692
21. Lebaudy C., Hulot J.S., Amoura Z., Costedoat-Chalumeau N., Serreau R., Ankri A., et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 84 3 (2008) 370-377
22. Sarig G., Vidergor G., and Brenner B. Assessment and managment of high-risk pregnancies in women with thrombophilia. Blood Rev 23 4 (2009) 143-147
23. Johann S., Zoller C., Haas S., Blumel G., Lipp M., and Forster R. Sulfated polysaccharide anticoagulants suppress natural killer cell activity in vitro. Thromb Haemost 74 (1995) 998-1002
24. Christopherson II K.W., Campbell J.J., Travers J.B., and Hromas R.A. Low molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 302 (2002) 290-295
25. Fritchley S.J., Kirby J.A., and Ali S. The antagonism of interferon-gamma (IFN-gamma) by heparin: examination of the blockade of class II MHC antigen and heat shock protein-70 expression. Clin Exp Immunol 120 (2000) 247-252
26. Hills F.A., Abrahams V.M., González-Timón B., Francis J., Cloke B., Hinkson L., et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Rep 12 4 (2006) 237-243
27. Alban B.C., Classen B., Brunner G., and Blaschek W. Differentiation between the complement modulating effects of an arabinogalactan-protein from Echinacea purpurea and heparin. Planta Med 68 (2002) 1118-1124
28. Groeneveld T.W., Oroszlán M., Owens R.T., Faber-Krol M.C., Bakker A.C., Arlaud G.J., et al. Interactions of extracellular matrix proteoglycans decorin and byglican with C1q and collectins. J Immunol 175 (2005) 4715-4723
29. a Edición Buenos Aires: Editorial Médica Panamericana; 1996. p. 386- 420.
30. Wouters D., Wiessenberg H.D., Hart M., Bruins P., Voskuyl A., Daha M.R., et al. Complexes between C1q and C3 or C4: Novel and specific markers for classical complement pathway activation. J Immunol Methods 298 (2005) 35-45
31. Albertí S., Marqués G., Hernández-Allés S., Rubires X., Tomás J.M., Vivanco F., et al. Interaction between complement subcomponente C1q and Klebsiella pneumoniae Porin OmpK36. Infect Immun 64 11 (1996) 4719-4725
32. Fishelson Z., Attali G., and Mevorach D. Complement and apoptosis. Mol Immunol 38 (2001) 207-219
33. Ganapathy R., Whitley G.S., Cartwright J.E., Dash P.R., and Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 22 9 (2007) 2523-2527
34. Calabrese G.C., Alberto M.F., Tubio R., Marani M.M., Fernández de Recondo M.E., Lazzari M., et al. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein. Thromb Res 113 (2004) 243-250
35. Alberto F., Romero Giaquinta D., Lazzari M., and Calabrese G.C. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Tromb Res 122 (2008) 109-116
36. Sheehan J.P., Kobbervig C.E., and Kirkpatrick H.M. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry 42 (2003) 11316-11325
37. Yuan Q.P., Walke E.N., and Sheehan J.P. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry 44 (2005) 3615-3625
38. Richani K., Soto E., Romero R., Espinoza J., Chaiworapongsa T., Nien J.K., et al. Normal pregnancy is characterized by a systemic activation of the complement system. J Matern Fetal Neonatal Med 17 4 (2005) 239-245
39. Johnson U., and Gustavii N. Complement components in normal pregnancy. Acta Pathol Microbiol Immunol Scand 95 (1987) 97-99
40. Mellembakken J.R., Hogasen K., Mollnes T.E., Hack C.E., Abyholm T., and Videm V. Increased systemic activation of neutrophils but not complement in preeclampsia. Obstet Gynecol 97 3 (2001) 371-374
41. Feng X., Tonnesen M.G., Peerschke E.I., and Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol 168 (2002) 2441-2448
42. Bulla R., Agostinis C., Bossi F., Rizzi L., Debeus A., Tripodo C., et al. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium.programmed cell death in human trophoblast. Mol Immunol 45 9 (2008) 2629-2640